|
1
|
Raue F and Frank-Raue K: Update multiple
endocrine neoplasia type 2. Fam Cancer. 9:449–557. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wagner SM, Zhu S, Nicolescu AC and
Mulligan LM: Molecular mechanisms of RET receptor-mediated
oncogenesis in multiple endocrine neoplasia 2. Clinics (Sao Paulo).
67(Suppl 1): S77–S84. 2012. View Article : Google Scholar
|
|
3
|
American Thyroid Association Guidelines
Task Force; Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib
H, Moley JF, Pacini F, Ringel MD, et al: Medullary thyroid cancer:
Management guidelines of the American thyroid association. Thyroid.
19:565–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qi XP, Ying RB, Ma JM, Liu WT, Du ZF, Fei
J, Yang CP, Song QZ, Jin HY, Chen ZG, et al: Case report: A p.C618S
RET proto-oncogene germline mutation in a large Chinese pedigree
with familial medullary thyroid carcinoma. Fam Cancer. 11:131–136.
2012. View Article : Google Scholar
|
|
5
|
Hibi Y, Ohye T, Ogawa K, Shimizu Y,
Shibata M, Kagawa C, Mizuno Y, Kurahashi H and Iwase K: A MEN2A
family with two asymptomatic carriers affected by unilateral renal
agenesis. Endocr J. 61:19–23. 2014. View Article : Google Scholar
|
|
6
|
Sakorafas GH, Friess H and Peros G: The
genetic basis of hereditary medullary thyroid cancer: Clinical
implications for the surgeon, with a particular emphasis on the
role of prophylactic thyroidectomy. Endocr Relat Cancer.
15:871–884. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roy M, Chen H and Sippel RS: Current
understanding and management of medullary thyroid cancer.
Oncologist. 18:1093–1100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferguson JW, Richard JJ, O'Laughlin JW and
Banks CV: Simultaneous spectrophotometric determination of calcium
and magnesium with chlorophosphonazo III. Anal Chem. 36:796–799.
1964. View Article : Google Scholar
|
|
9
|
Mulligan LM, Kwok JB, Healey CS, Elsdon
MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al:
Germ-line mutations of the RET proto-oncogene in multiple endocrine
neoplasia type 2A. Nature. 363:458–460. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Donis-Keller H, Dou S, Chi D, Toshima K,
Lairmore TC, Howe JR, Moley JF, Goodfellow P and Wells SA Jr:
Mutations in the RET proto-oncogene are associated with MEN 2A and
FMTC. Hum Mol Genet. 2:851–856. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gschwind A, Fischer OM and Ullrich A: The
discovery of receptor tyrosine kinases: Targets for cancer therapy.
Nat Rev Cancer. 4:361–370. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Machens A, Niccoli-Sire P, Hoegel J,
Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P,
Raue F, Conte-Devolx B, et al: Early malignant progression of
hereditary medullary thyroid cancer. N Engl J Med. 349:1517–1525.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pasini B, Ceccherini I and Romeo G: RET
mutations in human disease. Trends Genet. 12:138–144. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qi XP, Chen XL, Ma JM, Du ZF, Fei J, Yang
CP, Cheng J, Song QZ, Han JS, Jin HY, et al: RET proto-oncogene
genetic screening of families with multiple endocrine neoplasia
type 2 optimizes diagnostic and clinical management in China.
Thyroid. 22:1257–1265. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mulligan LM, Eng C, Healey CS, Clayton D,
Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H,
et al: Specific mutations of the RET proto-oncogene are related to
disease phenotype in MEN 2A and FMTC. Nat Genet. 6:70–74. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Santoro M, Carlomagno F, Romano A, Bottaro
DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH,
et al: Activation of RET as a dominant transforming gene by
germline mutations of MEN2A and MEN2B. Science. 267:381–383. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sippel RS, Kunnimalaiyaan M and Chen H:
Current management of medullary thyroid cancer. Oncologist.
13:539–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sawka AM, Jaeschke R, Singh RJ and Young
WF Jr: A comparison of biochemical tests for pheochromocytoma:
Measurement of fractionated plasma metanephrines compared with the
combination of 24-hour urinary metanephrines and catecholamines. J
Clin Endocrinol Metab. 88:553–558. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Milan SA, Sosa JA and Roman SA: Current
management of medullary thyroid cancer. Minerva Chir. 65:27–37.
2010.PubMed/NCBI
|
|
20
|
Roman S, Lin R and Sosa JA: Prognosis of
medullary thyroid carcinoma: Demographic, clinical and pathologic
predictors of survival in 1252 cases. Cancer. 107:2134–2142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scollo C, Baudin E, Travagli JP, Caillou
B, Bellon N, Leboulleux S and Schlumberger M: Rationale for central
and bilateral lymph node dissection in sporadic and hereditary
medullary thyroid cancer. J Clin Endocrinol Metab. 88:2070–2075.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fleming JB, Lee JE, Bouvet M, Schultz PN,
Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF and
Evans DB: Surgical strategy for the treatment of medullary thyroid
carcinoma. Ann Surg. 230:697–707. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
White ML, Gauger PG and Doherty GM:
Central lymph node dissection in differentiated thyroid cancer.
World J Surg. 31:895–904. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen H, Sippel RS, O'Dorisio MS, Vinik AI,
Lloyd RV and Pacak K; North American Neuroendocrine Tumor Society
(NANETS): The North American Neuroendocrine Tumor Society consensus
guideline for the diagnosis and management of neuroendocrine
tumors: Pheochromocytoma, paraganglioma, and medullary thyroid
cancer. Pancreas. 39:775–783. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krampitz GW and Norton JA: RET gene
mutations (genotype and phenotype) of multiple endocrine neoplasia
type 2 and familial medullary thyroid carcinoma. Cancer.
120:1920–1931. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rodriguez JM, Balsalobre M, Ponce JL, Ríos
A, Torregrosa NM, Tebar J and Parrilla P: Pheochromocytoma in MEN
2A syndrome. Study of 54 patients. World J Surg. 32:2520–2526.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Inabnet WB, Caragliano P and Pertsemlidis
D: Pheochromocytoma: Inherited association, bilaterality and cortex
preservation. Surgery. 128:1007–1011. 2000. View Article : Google Scholar
|
